苑东生物(688513.SH)公告称，全资子公司硕德药业于近日收到国家药监局核准签发的《药品注册证 书》，药品名称为培哚普利氨氯地平片（Ⅲ）。该药品为复方制剂，主要用于治疗 高血压。培哚普利 氨氯地平片（Ⅲ）由法国施维雅开发，最早于2008年3月在欧盟获批上市。硕德药业该药品获批后视同 通过一致性评价。根据米内网数据，2024年该药品销售金额约4.36亿元。 ...

Group 1: Company Performance - Jinli Permanent Magnet expects a net profit of 300 million to 335 million yuan for the first half of 2025, representing a year-on-year increase of 151% to 180% [2] - Zhongji Xuchuang anticipates a net profit of 3.6 billion to 4.4 billion yuan for the first half of 2025, reflecting a growth of 52.64% to 86.57% compared to the previous year [4] - China Galaxy forecasts a net profit of 6.362 billion to 6.801 billion yuan for the first half of 2025, indicating a year-on-year increase of 45% to 55% [5] - Meili Technology projects a net profit increase of 66.85% to 92.52% for the first half of 2025 [8] - Blue Ocean Huaten expects a net profit growth of 152.76% to 190.68% for the first half of 2025 [7] Group 2: Shareholder Actions - China Life intends to reduce its stake in Hangzhou Bank by no more than 0.7%, equating to approximately 50.79 million shares [2] - Zhongsheng High-Tech is planning a transfer of 22.35% of its shares, potentially leading to a change in control, with a transaction value of 2.5 billion yuan [3] - Fangzheng Technology's major shareholder plans to reduce its stake by no more than 2.27% [10] Group 3: Investment Activities - Bertley plans to invest 198 million yuan in a partnership focused on high-growth unlisted companies in humanoid robotics and automotive intelligence [3] - Rock Mountain Technology's subsidiary is participating in an investment fund targeting Bytedance Ltd, with a commitment of 20.32 million yuan [6] - Zhonghua International is planning to acquire 100% of Nantong Xingchen's equity, leading to a temporary suspension of its stock [2]